Skip to content

Innoviva, Inc. INVA Accrued revenue share

Accrued revenue share at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$53.66M

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.4B+9.7%
P/E3.5×
P/S4.1×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ReceivablesLongTermContractsOrPrograms.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s accrued revenue share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s accrued revenue share?
Innoviva, Inc. (INVA) reported accrued revenue share of $58.62M in Q1 2026.
How has Innoviva, Inc.'s accrued revenue share changed year-over-year?
Innoviva, Inc.'s accrued revenue share decreased by 4.3% year-over-year, from $61.26M to $58.62M.
What is the long-term trend for Innoviva, Inc.'s accrued revenue share?
Over 4 years (2021 to 2025), Innoviva, Inc.'s accrued revenue share has grown at a -14.8% compound annual growth rate (CAGR), from $110.71M to $58.35M.
What does accrued revenue share mean?
This represents the value of royalty or revenue-sharing arrangements that have been earned based on contractual performance but have not yet been invoiced or collected. It serves as a leading indicator of cash inflows from licensing or partnership agreements. Monitoring this balance helps investors assess the timing and reliability of royalty-based income streams.